Robert Grove, Ph.d.
Dr. Grove received a B. A. in Zoology at Goshen College, in Goshen, Indiana.
After entering graduate school at the University of South Florida, he earned a Master's Degree in Marine Biology studying the biochemistry of sea anemone venom.
Dr. Grove continued his graduate education by earning a Ph.D. in Medical Biochemistry in the College of Medicine at the University of South Florida.
was granted a post-doctoral fellowship at NIEHS-NIH, where he
studied the cell biology and biochemistry of progenitor cells involved in cranio-facial development.
After a short tenure as a staff fellow at NIEHS
, Dr. Grove
accepted a position in the Cardiovascular Division of Bristol Myers Squibb, where he
focused on development of cholesterol synthesis inhibiting drugs and liver cell function.
After Bristol Myers Squibb, Dr. Grove worked at several biotechnology companies, where he specialized in gene therapy, photodynamic therapy, and cell therapy.
In 2005 he joined EndGenitor Technologies to develop a cord blood derived endothelial progenitor cell into a viable therapeutic candidate for patients with compromised peripheral circulation.
Dr. Grove has considerable experience in initiating, building, and directing successful cardiovascular programs.
Having published more than 40 scientific papers, Dr. Grove
has enjoyed his
experience in both biotechnology and large pharmaceutical companies.
Chief Scientific Officer
Robert Grove, Ph.D.
EndGenitor Technologies, Inc